Form D · Biotechnology
KaloCyte, Inc.
St. Louis, MO · CIK 0001738542
Offering snapshot reported May 8, 2018 · SEC filing
- Reported sold
- $800K Offering amount: $800K
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Apr 27, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 8, 2018 | Initial | $800,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-311892
Source: Form D, filed May 8, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Allan Doctor | Director, Executive |
| Daniel Getman | Director |
| Gregory Lanza | Director |
| Dipanjan Pan | Director |
| Philip Spinella | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4320 Forest Park Suite 302
St. Louis, MO, 63108
St. Louis, MO, 63108